Current perspectives on BRCA1- and BRCA2-associated breast cancers

Internal Medicine Journal

Volumn 31, Issue 6, 2001, Pages 349-356

  Phillips, Kelly A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

BRCA1; BRCA2; Breast cancer; Genetics

Indexed keywords

BRCA2 PROTEIN;

AUSTRALIA; BIOLOGY; BREAST CANCER; CANCER RESEARCH; CANCER RISK; COHORT ANALYSIS; DNA MODIFICATION; FAMILIAL CANCER; FAMILY HISTORY; GENE EXPRESSION; GENE MUTATION; GENETIC RISK; HUMAN; ONCOGENE; OVARY CANCER; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANIMALS; AUSTRALIA; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE (GENETICS); MALE; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0035569461     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2001.00075.x     Document Type: Review

References (53)

1. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
2. Identification of the breast cancer susceptibility gene BRCA2
3. Australia takes two-step approach on genetic studies
4. Family history and the risk of breast cancer: A systematic review and meta-analysis
5. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale
6. Prevalence of BRCA1 and BRCA2 mutations in patients with early-onset breast cancer
7. The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins
8. Internal repeats in the BRCA2 protein sequence
9. RAD51 interacts with the evolutionary conserved BRC motifs in the human breast cancer susceptibility gene BRCA2
10. The BRCA2 is a histone acetyltransferase
11. What's mice got to do with it?
12. Targeted mutations of the breast cancer susceptibility gene homologs in mice: Lethal phenotypes of BRCA1, BRCA2, BRCA1/BRCA2, BRCA1/p53 and BRCA2/p53 nullizygous embryos
13. Thymic lymphomas in mice with a truncating mutation in BRCA2
14. A polymorphic stop codon in BRCA2
15. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
16. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women
17. Prevalence of BRCA1 and BRCA2 mutations in patients with early-onset breast cancer
18. BRCA1 mutations in a population-based sample of young women with breast cancer
19. BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 and in women before age 45 years with first degree family history
20. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women
21. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2
22. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
23. Risks of cancer in BRCA1-mutation carriers
24. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
25. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
26. Cancer risks in BRCA2 mutation carriers
27. Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germline mutation carriers
28. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation
29. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study
30. Variation in cancer risks by mutation position in BRCA2 mutation carriers
31. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
32. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes
33. BRCA1 inhibition of estrogen receptor signaling in transfected cells
34. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
35. Oral contraceptives and the risk of hereditary ovarian cancer
36. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat
37. The APC I1307K allele and breast cancer risk
38. BRCA1 mutations in primary breast and ovarian carcinomas
39. BRCA2 mutations in primary breast and ovarian cancers
40. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors
41. Loss of heterozygosity in sporadic breast tumors at the BRCA2 locus on chromosome 13q12-q13
42. Localization of human BRCA1 and its loss in high grade non-inherited breast carcinomas
43. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: A correlation with other biological parameters
44. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers
45. Methylation of the BRCA1 gene in sporadic breast cancer
46. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells
47. Overexpression of BRCA2 gene in sporadic breast tumors
48. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?
49. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations
50. Tumour biological features of BRCA1-induced breast and ovarian cancer
51. Background rationale and protocol for a case-control family study of breast cancer
52. KConFab: A research resource of Australasian breast cancer families